This content is from: Innovation

TPG Capital Buys Immucor For $1.97B

TPG Capital will acquire Immucor for $1.97 billion.

TPG Capital will acquire Immucor for $1.97 billion. The shares of the company, which provides automated instrument-reagent systems to the blood transfusion industry, will be purchased by TPG’s investment funds for $27 a share.

Goldman Sachs served as financial advisor to Immucor. Citi and JP Morgan Securities were the financial advisors and provided complete financing to the private equity firm.

Click here for the release from Immucor.

Related Content